dogs

/Tag:dogs
­

Bionaturis Leishmaniasis Vaccine Granted in USA

 

This new concession in USA joins the one already obtained by Bionaturis in China last September for the same patent family.

 

Each year 80 million dogs are in danger of developing the disease in the affected areas of Europe and America. Visceral leishmaniasis affects more than 700,000 people worldwide each year, with the dog being the main reservoir of the disease.

 

The granted patent protects the use of the intended vaccine in dogs and humans.

 

Bionaturis goes one step further in the pet market, which according to Euromonitor International represented 93,000 million euros in 2015.

 

The Centro de Desarrollo Tecnologico e Industrial (CDTI) has also granted Bionaturis a non-refundable incentive worth 196,300 euros to support the achievement of a new intermediate milestone in the development of the vaccine.

 

Jerez de la Frontera, February XX, 2018.- The US Patent and Trademark Office (USPTO) has granted the patent for the prevention and treatment of visceral leishmaniasis in both dogs and humans to the vaccine against this disease, which Bionaturis holds the worldwide exclusivity. The lead vaccine program, called internally BNT005, comes originally from the CSIC (Spanish National Council of Research)

 

Currently, BNT005 is the subject of an Evaluation and Options (E&O) agreement with an international sponsor for the exclusive sublicense of the registration and commercialization of BNT005 for use in dogs worldwide, except Argentina and Paraguay, where it has been already licensed for the same purpose to the Argentine laboratory Biotandil.

 

Visceral leishmaniasis affects between 700,000 and 1,000,000 people each year and has a mortality rate of 3%, according to data provided by the World Health Organization (WHO). In Spain, it is estimated that around 300 people suffer each year. It is a tropical disease that is transmitted through the bite of insects. The […]

February 21st, 2018|Blog english, Hechos Relevantes|Comments Off on Bionaturis Leishmaniasis Vaccine Granted in USA

Bionaturis out-licenses its Leishmaniasis vaccine for Argentina and Paraguay

Bionaturis has signed an exclusive development, manufacturing, registration, and commercialization license of its Leishmaniasis vaccine with the company Biotandil for Argentina and Paraguay
According to the terms of the license, Bionaturis will receive 50% of the profits resulting of the commercialization.
The immunization of these animals –the main reservoir of this neglected tropical disease- is crucial to avoid zoonosis episodes

 

Jerez de la Frontera, April 25, 2017.  Bionaturis has signed an exclusive development, manufacturing, registration, and commercialization license of its Leishmaniasis lead vaccine (BNT005) with the company Laboratorio Biologico de Tandil (Biotandil) for Argentina and Paraguay as the Territory. According to the terms of the license, Biotandil will be responsible for the manufacturing, development, registration, and commercialization of the vaccine in the territory. In exchange Bionaturis will receive 50% of the profits resulting of the commercialization.

Visceral Canine Leishmaniasis is a so called neglected tropical disease transmitted by the bite of the phlebotomine sandfly that acts as a vector. One of its main reservoir –spread through the Mediterranean countries and LATAM – are dogs, and therefore their immunization is crucial to minimize zoonosis episodes. According to WHO, in humans between 700.000 and 1.000.000 new cases, with 3% of deaths, are registered annually worldwide. In Argentina, there is in place a Leishmaniasis National Programme led to track its progress in the country and promoting control and eradication measures.

“This specific license of our Leishmaniasis vaccine candidate means a significant milestone because LATAM is one of the most affected regions by this disease, being recorded a steady growth in Argentine and Paraguay lately. Besides, getting the market authorization in Argentina could pave the way for its registration in other Latin American markets”, the chief of biological developments in Bionaturis, Juan Jose Infante, […]

April 25th, 2017|Blog english, Press Releases|Comments Off on Bionaturis out-licenses its Leishmaniasis vaccine for Argentina and Paraguay

Bionaturis’ vaccine against Visceral Canine Leishmaniasis, preventive and therapeutic

Bionaturis continues the development of BNT005, a vaccine against Visceral Canine Leishmaniasis, a disease that affects dogs and is spread in Mediterranean countries as Spain, being registered an increasing rate of zoonosis (when an animal disease infects humans) lately. The visceral one is the most serious type of Leishmaniasis and it can be lethal if it is not treated well. It is caused by the parasites Leishmania and transmitted by the bite of the phlebotomine sandfly that acts as a vector.

Nowadays there is not any vaccine already in the market to prevent or treat humans against this disease, being its development a priority of the World Health Organization (WHO). The current treatment with antiparasitics has undesirable side effects and it causes the outbreak of resistance phenomena in the parasite. However, for dogs there are few options approved in Europe and LATAM, that claim themselves as prophylactic but not therapeutic.

Dogs among rabbits are the main reservoir of Leishmaniasis. Because of that, its control is essential to avoid the spread of this disease in humans (zoonosis). “A vaccine against canine Leishmaniasis has a double goal. Firstly, in the animals, which will be protected or can be treated against a disease that is fatal in a high percentage of cases. And, secondly, in humans, who will have less possibilities of suffering the disease if their pets do not have the parasite or they have them under control”, Bionaturis’ CSO, Juan Jose Infante, has stated.

Tests in rodents and Beagle dogs

Infante has also stood out that “the difference between BNT005 by Bionaturis and others vaccine attempts to fight this disease is that the preliminary results obtained and published in the last annual management report show that Bionaturis’ vaccine induces an […]

August 12th, 2014|Blog english, Press english|Comments Off on Bionaturis’ vaccine against Visceral Canine Leishmaniasis, preventive and therapeutic

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR